KP 0936S
Alternative Names: KP-0936SLatest Information Update: 23 Jun 2022
At a glance
- Originator Kangpu Biopharmaceuticals
- Class Antineoplastics; Small molecules
- Mechanism of Action Ubiquitin protein ligase complex modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cancer
Most Recent Events
- 17 Jun 2022 Preclinical trials in Cancer in China, prior to June 2022 (Kangpu Biopharmaceuticals pipeline June 2022)